RxDoctor Payments Data

Patrick Reilly, MD

Gastroenterology · Pensacola, FLNPI 1568559938

Payments from drug & device makers

$6,052in general payments, 2019–2025

Across 241 payments — averaging $25.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Medtronic$1K
  • Johnson & Johnson$762
  • Takeda Pharmaceuticals U.S.A., Inc.$496
  • Phathom Pharmaceuticals, Inc.$259
  • Boston Scientific$248
  • plus $1K from 21 others

What the payments were for

  • Travel & lodging$80413%
  • Food & beverage$5,14985%
  • Education$992%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,052 in reported general payments places this provider in the 60th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$343,133
Medicare patients
647
Services billed
9,447

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab29$838,863
CreonLipase/Protease/Amylase27$147,486
Humira(Cf) PenAdalimumab17$135,347
LinzessLinaclotide22$27,804
VoqueznaVonoprazan Fumarate13$9,251
Promethazine Hcl90$4,756
Colesevelam Hcl21$3,373
Azathioprine11$2,083
Omeprazole132$2,054
Pantoprazole Sodium151$1,640
Esomeprazole Magnesium62$1,459
Sucralfate19$1,293
Metoclopramide Hcl33$967
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates14$818
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine27$818

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$762$838,86329 claims
AbbVieCreon, Linzess$1,744$175,29049 claims
Phathom Pharmaceuticals, Inc.Voquezna$259$9,25113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →